Stories about Doctor of Philosophy

Subscribe to topic

Subscribe to Doctor of Philosophy

24.10.2019 – 12:47
Technische Universität München
The quantum internet is within reach: Secure communication between quantum computers implemented
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35764/ High resolution images: https://mediatum.ub.tum.de/1522135 NEWS RELEASE The quantum internet is ...
17.10.2019 – 11:13
Technische Universität München
How roots grow hair: "Smoke detectors" in plants also control the growth of root hair
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35739/ High resolution images: https://mediatum.ub.tum.de/1521816 NEWS RELEASE How roots grow hair "Smoke detectors" in plants also control the growth of ...
13.08.2019 – 14:15
Helmholtz Zentrum München
BART-Seq: A Novel Method to Characterize Genes with High-Precision in Single Cells
The analysis of gene products in cells is an important tool for diagnosing disease and the design of new active substances in biological and medical research. At Helmholtz Zentrum München, a method of targeted RNA sequencing (transcriptome analysis) has now been developed, which precisely detects the smallest amounts of gene transcripts in single cells. The method ...
09.08.2019 – 16:37
Technische Universität München
Employees less upset at being replaced by robots than by other people
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35645/ NEWS RELEASE Employees less upset at being replaced by robots than by other people Study assesses psychological impact of job losses through ...
03.07.2019 – 20:29
voestalpine AG
EANS-General Meeting: voestalpine AG / Resolutions of the General Meeting
issuer: voestalpine AG voestalpine-Straße 1 A-4020 Linz phone: +43 50304/15-9949 FAX: +43 50304/55-5581 mail: IR@voestalpine.com WWW: www.voestalpine.com ISIN: AT0000937503 indexes: ATX, WBI stockmarkets: Wien language: English ...
02.05.2019 – 14:08
Helmholtz Zentrum München
Pluripotency or differentiation - that is the question
Would you like to read the message online? This way!
05.03.2019 – 10:04
Zentiva
The Parc Awards Championing Rising Talent in Drug Research & Development
Prague (ots/PRNewswire) - The Parc (Pharmaceutical Applied Research Center) is marking its five-year anniversary by launching The Parc Awards at a ceremony held at Zentiva Headquarters in Prague on March 5th. The Parc is a unique research platform designed to benefit future generations of scientists. "We are proud to be working alongside the next generation of ...
28.02.2019 – 10:46
Technische Universität München
A positron trap: first step on the way a matter-antimatter plasma
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35264/ High resolution image: https://mediatum.ub.tum.de/1479938 NEWS RELEASE A trap for positrons Interview with Dr. Eve Stenson on the delicate antiparticles of electrons For the first time, scientists ...
11.02.2019 – 23:55
Merck KGaA
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
28.01.2019 – 10:30
Vodafone Institut für Gesellschaft und Kommunikation GmbH
German Chancellor Angela Merkel opens Vodafone Institute's Digitising Europe Summit in Berlin on 19 February
Berlin (ots) - True to the motto 'The Future of Made in Europe', the Vodafone Institute will assemble international business executives, tech start-up founders, scientists in Berlin on 19 February. They will be joined by experts from the digital scene and civil society to discuss their vision for a digital Europe. ...
17.12.2018 – 14:43
Jacobs University Bremen
2
German Research Foundation supports new theoretical physics project at Jacobs University Bremen
14.12.2018 – 14:48
Jacobs University Bremen
5
Lucie Knor: From Bremen to Hawai'i - to conduct research
29.11.2018 – 16:31
Marinomed Biotech AG
EANS-Adhoc: Marinomed Biotech AG suspends offer period of the current IPO
issuer: Marinomed Biotech AG Veterinärplatz 1 A-1210 Wien phone: 0043250774460 FAX: 0043250774493 mail: office@marinomed.com WWW: www.marinomed.com ISIN: AT0000A1WD52, ATMARINOMED6 indexes: stockmarkets: Wien language: English ...
29.11.2018 – 15:26
Marinomed Biotech AG
EANS-Adhoc: Marinomed Biotech AG suspends offer period of the current IPO
issuer: Marinomed Biotech AG Veterinärplatz 1 A-1210 Wien phone: 0043250774460 FAX: 0043250774493 mail: office@marinomed.com WWW: www.marinomed.com ISIN: AT0000A1WD52 indexes: stockmarkets: Wien language: English ...
26.11.2018 – 18:07
Jacobs University Bremen
4
Research project on environmental impacts of deep-sea mining
26.11.2018 – 10:01
Kyowa Kirin International PLC
Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...
19.11.2018 – 13:08
Merck KGaA
Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...
12.11.2018 – 14:01
Leonovus Inc.
Leonovus Publishes Galaxa Whitepaper
Singapore and Ottawa, Ontario (ots/PRNewswire) - Leonovus Inc., ("Leonovus" or the "Company") (TSXV: LTV)(OTC: LVNSF) at a press conference in Singapore, announced the release of Ver 1.0 of the Galaxa Whitepaper. The news conference in Singapore aligned with Leonovus' participation in the Canadian Trade Mission to the Singapore Fintech Festival . Singapore is a major global blockchain hub. "We are proud to release this ...
06.11.2018 – 15:30
Jacobs University Bremen
4
Learning by doing: Jacobs students on a training cruise with the Heincke research vessel
05.11.2018 – 17:07
Helmholtz Zentrum München
Tackling Big Data - new graduate school for Data Science in Munich
As a result of digitalization, research is producing ever larger and more complex data sets. While these hold great potential for example for biomedicine, energy research, geo-research or robotics, they also need to be managed and interpreted. To address this need, the Munich School for Data Science @ Helmholtz, TUM & LMU (MuDS) has ...
Online version
01.11.2018 – 11:05
Jacobs University Bremen
4
More students and highly satisfied graduates at Jacobs University
25.10.2018 – 13:34
Helmholtz Zentrum München
Two-pronged approach - Novel combined therapy tackles excess fatty tissue
A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for ...
Online Version
23.10.2018 – 14:00
Debiopharm International SA
GenePOC® launches its GenePOC® CDiff test in Canada
Québec, Canada (ots) - GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC Inc., member of the Debiopharm Group, is proud to announce the approval by Health Canada and the launch of its GenePOC CDiff assay to be used with the revogene(TM) instrument. About the Clostridium difficile infection (CDI) In Canada, CDI is the main ...
17.10.2018 – 13:31
Accuray
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized ...
26.09.2018 – 15:05
Jacobs University Bremen
3
THE Ranking: Jacobs University Bremen among the top 300 universities worldwide
14.09.2018 – 14:00
Jacobs University Bremen
Emmy Noether Fellow is doing research at Jacobs University Bremen
11.09.2018 – 14:31
Merck KGaA
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

12Next